GenSight Biologics announced on October 8, 2026 the successful completion of a €1.0 million fundraising supported by existing shareholders Heights Capital and Invus. The biopharma company focuses on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The new financing follows a similar structure of shares and warrants, including pre-funded warrants, to the transaction completed in March 2026.
Fundraising Structure and Terms
The fundraising was carried out through the issuance of 2,597,404 ordinary shares, 11,940,300 pre-funded warrants, and 14,537,704 investor warrants. Investors could choose between shares with attached investor warrants and pre-funded warrants with attached investor warrants. The issue price was €0.0770 per ABSA and €0.0670 per pre-paid unit, while each investor warrant carries an exercise price of €0.0497.
Use of Proceeds and Cash Runway
GenSight reported gross proceeds of €1.0 million and net proceeds of approximately €0.95 million. The company will use the funds to finance operating activities and working capital requirements pending the structural financing of the RECOVER Phase III trial. This financing covers part of a near-term funding requirement of up to €2 million disclosed on September 29 and October 7, 2026, and the company expects to cover the balance by the end of November 2026.
Funding Outlook and Going Concern
The company expects that the current financing, together with additional early access treatment cash inflows or new debt, will fund operations until late March 2027. At that point, the first significant payments related to the preparation of the RECOVER trial become due. The company continues to work on securing the structural financing required for the RECOVER Phase III trial, and if such financing is not obtained by March 2027, the start of RECOVER would be postponed.
Shareholder Impact and Admission
Before the fundraising, GenSight's share capital consisted of 243,619,926 ordinary shares, and after the issuance of the offered shares it will rise to 246,217,330 ordinary shares. Existing shareholders who did not participate will see their stake of 1.00% decrease to 0.99% on a non-diluted basis immediately after completion. The offered shares are expected to be admitted to trading on Euronext Paris on October 12, 2026, while the warrants will not be listed on any venue.
Management Commentary and Strategic Progress
Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics, thanked the two existing shareholders for renewing their support on the same terms as in March. He noted that paid early access programs have generated more than €8 million collected since March and that the manufacturing process has been successfully transferred to Catalent. The company is preparing the RECOVER Phase III trial, with a CRO selected and a meeting with the FDA to finalize the protocol before year-end.
Risk Factors and Forward-Looking Considerations
GenSight cautioned that its funding requirements continue to indicate a material uncertainty that may cast significant doubt on its ability to continue as a going concern. The company's cash flow projections do not assume any exercise of the warrants issued in this fundraising, though full exercise would generate additional gross proceeds of approximately €0.8 million. Existing shareholders may experience further dilution from warrant exercises or future securities transactions, and the market price of the company's shares could fluctuate significantly.
GenSight Biologics has strengthened its near-term cash position through a targeted €1.0 million fundraising from existing investors. The transaction supports ongoing operating activities while the company continues to pursue structural financing for the RECOVER Phase III trial. With additional early access revenues and a transferred manufacturing process, the company is focused on advancing its clinical development program despite the acknowledged going concern uncertainty.